The FDA’s drug approval process is changing fast. AI companies are now helping review new medicines. This shift comes as the agency faces staff shortages and growing workloads. Tech giants bring powerful tools that can analyze medical data in minutes instead of months. They’re checking for safety issues and predicting how drugs might interact with the body. What does this mean for patients waiting for new treatments? The answer may reshape medicine forever.
As the pharmaceutical industry navigates through 2025, the FDA is experiencing unprecedented changes that could reshape how medicines reach American patients. Since January, tectonic shifts have occurred in healthcare foundations, making this year vital for drug approvals.
The FDA has continued approving novel drugs – medications never before marketed in the US. New Molecular Entity and New Therapeutic Biological Product approvals progressed through February, with multiple decisions expected in May.
A major disruption began in mid-February with an initial wave of terminations across the FDA. This was followed by a broader reduction of 10,000 staffers throughout the Department of Health and Human Services.
While medical device and drug reviewers were supposed to be exempt, approximately 20% of discharged staffers may have been terminated by mistake. These staffing shortages are now being linked to potential delays in medicine approvals.
The approval process itself appears to be fundamentally changing, creating ripple effects that could impact other regulatory agencies worldwide, including the European Medicines Agency.
Several significant drugs are awaiting FDA decisions. Suzetrigine, a non-opioid alternative for moderate-to-severe acute pain, had an expected decision date of January 30. Other promising candidates include semaglutide, nipocalimab, and fam-trastuzumab deruxtecan-nxki – all targeting essential unmet medical needs.
The FDA had granted suzetrigine both fast track and breakthrough therapy designations. These special designations help accelerate the approval process for treatments showing substantial improvement over available therapies.
Suzetrigine’s potential approval is especially important for pain management. With opioids being the leading cause of fatal drug overdoses in 2023 and prescription opioids accounting for over 12% of these deaths, developing non-addictive pain medications remains vital.
As the FDA undergoes these transformations, the implications run deeper than just timing issues. The agency sets global standards for drug regulation, meaning disruptions in FDA operations could affect regulatory agencies worldwide, potentially changing how drugs are evaluated and approved everywhere.
Among the closely watched therapies is Moderna’s next-generation COVID-19 vaccine (mRNA-1283), which has demonstrated noninferiority to Spikevax with a PDUFA date of May 31, 2025.
A recent communications freeze affecting the FDA’s public outreach has further complicated the situation, with limited press releases and publications since the beginning of the year.
Similar to the financial risks associated with expensive geothermal energy investments, pharmaceutical companies face significant uncertainties when navigating the current FDA approval landscape.
References
- https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2025
- https://www.fda.gov/drugs/development-approval-process-drugs/novel-drug-approvals-fda
- https://www.rheumatologyadvisor.com/news/fda-drug-approval-decisions-expected-may-2025/
- https://fleishmanhillard.com/2025/04/is-the-u-s-approval-process-for-new-medicines-fundamentally-changing/
- https://www.bipc.com/4-potential-fda-drug-approvals-to-watch-in-2025
